title: Comparison of adapalene 0.1% solution and tretinoin 0.025% gel in the topical treatment of acne vulgaris.
abstract: A multicentre study was conducted to compare clinical safety and efficacy of adapalene 0.1% solution and tretinoin 0.025% gel, both topical treatments for acne, in a once-daily dosage regimen for 12 weeks. A total of 297 patients were enrolled by eight investigators in this randomized, investigator-masked study in a parallel group design. An open label period using adapalene followed this study to assess the long-term safety of adapalene solution. Adapalene and tretinoin proved to be clinically and statistically effective in treating acne by reducing inflammatory (47% and 50%, respectively) and non-inflammatory lesions (57% and 54%) as compared to baseline. When comparing patients who had 75% or greater improvement in open comedones, adapalene was shown to be significantly more effective than tretinoin. No serious adverse event was reported during this study, including during the long-term period. The reactions that occurred were similar between treatments, i.e. burning, pruritus, scaling, dryness and erythema.
authors.affiliation: Department of Dermatology, University of Michigan Medical School, Ann Arbor, USA.
authors.forename: C N
authors.initials: CN
authors.lastname: Ellis
authors.forename: L E
authors.initials: LE
authors.lastname: Millikan
authors.forename: E B
authors.initials: EB
authors.lastname: Smith
authors.forename: D M
authors.initials: DM
authors.lastname: Chalker
authors.forename: L J
authors.initials: LJ
authors.lastname: Swinyer
authors.forename: I H
authors.initials: IH
authors.lastname: Katz
authors.forename: R S
authors.initials: RS
authors.lastname: Berger
authors.forename: O H
authors.initials: OH
authors.lastname: Mills
authors.forename: M
authors.initials: M
authors.lastname: Baker
authors.forename: M
authors.initials: M
authors.lastname: Verschoore
authors.forename: C
authors.initials: C
authors.lastname: Loesche
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000068816:Adapalene; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D004311:Double-Blind Method; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D005782:Gels; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009281:Naphthalenes / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014212:Tretinoin / Q000008:administration & dosage* / Q000009:adverse effects